BPC-157 vs TB-500: Which Healing Peptide Is Right For You?

BPC-157 is generally favored for acute tendon and ligament injuries. Sikiric et al. (2018, PMID 29337192) and the broader BPC-157 research literature show angiogenic and tendon-to-bone healing effects in rodent models, particularly when injected near the injury site. TB-500 is more often chosen for systemic, multi-site, or chronic recovery rather than a single tendon issue. Many users stack both for serious injuries (see our combined protocol guide).

TB-500 has a substantially longer functional half-life. Native thymosin beta-4 and the TB-500 fragment are detectable systemically for days after injection, supporting a twice-weekly or weekly dosing pattern. BPC-157 has a much shorter systemic half-life (hours), which is why most BPC-157 protocols use daily (or twice-daily) subcutaneous injections.

Stacking BPC-157 and TB-500 is common practice in injury-recovery protocols because the two peptides work through complementary mechanisms — BPC-157 drives local angiogenesis and growth-factor modulation, while TB-500 drives systemic cell migration and actin remodeling. Our /learn/bpc-157-tb-500-protocol guide covers the stacking schedule, dosing, and cycle structure in detail.

BPC-157 has a larger published preclinical literature, mostly from Sikiric and colleagues, covering gastrointestinal, tendon, ligament, and neurological models. TB-500 derives from thymosin beta-4 research, which has a substantial cardiovascular and wound-healing literature (Bock-Marquette 2004; Philp 2007) but fewer studies on the synthetic TB-500 fragment specifically. Neither peptide has robust controlled human clinical trials for the indications most commonly discussed in recovery communities.

BPC-157 is typically dosed at 250–500 mcg subcutaneously once or twice daily, often injected near the injury site for localized effect. TB-500 is dosed at 2–2.5 mg twice weekly for a 4–6 week loading phase, then 2 mg weekly maintenance. Conservative starts are advised for both; titrate up only after assessing tolerance.

Neither BPC-157 nor TB-500 is FDA-approved for any human use. Both are sold as research chemicals and are explicitly prohibited by WADA for competitive athletes. The FDA placed BPC-157 on the Section 503A compounding "Category 2" list in 2024, restricting compounding pharmacies from preparing it. Consult a licensed healthcare provider before any use.

TB-500 is typically priced higher than BPC-157 per milligram. Research-grade 5 mg vials range roughly $30–60 for BPC-157 and $40–80 for TB-500 in the US gray market, though pricing varies significantly by vendor, batch testing, and recent regulatory pressure on compounding.

TB-500 has more relevant mechanistic basis for hair-follicle effects — Philp et al. (2007, PMID 17470963) documented thymosin beta-4 effects on hair follicle development and wound-related re-epithelialization. BPC-157 is not typically used for hair indications. Note that hair regrowth claims for both peptides are largely anecdotal in the absence of controlled trials.

BPC-157 users typically report subjective improvement in acute injuries within 1–3 weeks of consistent daily dosing, with faster effects when injected near the injury site. TB-500 onset is generally slower (2–4 weeks), reflecting its systemic distribution and longer half-life. For chronic injuries, both peptides typically require 6–8 weeks before meaningful improvement is reported.

BPC-157 has the stronger mechanistic and preclinical basis for gastrointestinal effects. It was originally isolated from gastric juice and the body-protective compound research (Sikiric et al., 2016 PMID 27510481) centers on intestinal protection, anti-inflammatory effects, and recovery from NSAID-induced damage. TB-500 is not typically used for gut indications.

Yes. Both peptides are heavily counterfeited in the unregulated research-chemical market, with reports of underdosed, mislabeled, or completely substituted product. Always require recent third-party Certificates of Analysis (COA) showing HPLC purity and mass-spec identity verification, and prefer vendors with consistent batch documentation. See our COA Reading Guide for detail.

Both peptides are well-tolerated in user reports, with side effects generally limited to injection-site reactions, mild systemic fatigue early in dosing, and occasional dizziness. TB-500 has a theoretical cancer concern due to its pro-angiogenic and pro-cell-migration mechanism; both peptides should be avoided in anyone with active malignancy. Long-term human safety data for either compound is essentially absent.